Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tempest Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TPST
Nasdaq
8731
https://www.tempesttx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tempest Therapeutics Inc
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
- Apr 9th, 2024 12:00 pm
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
- Apr 4th, 2024 12:00 pm
Tempest Reports Year End 2023 Financial Results and Provides Business Update
- Mar 19th, 2024 8:25 pm
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
- Mar 12th, 2024 12:00 pm
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
- Mar 5th, 2024 9:30 pm
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
- Feb 26th, 2024 1:00 pm
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Feb 2nd, 2024 9:30 pm
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
- Nov 20th, 2023 1:00 pm
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 8th, 2023 10:17 pm
Tempest Therapeutics, Inc.'s (NASDAQ:TPST) largest shareholders are private equity firms who were rewarded as market cap surged US$127m last week
- Oct 12th, 2023 11:42 am
Tempest Adopts Limited Duration Stockholder Rights Plan
- Oct 11th, 2023 12:01 pm
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
- Oct 11th, 2023 12:00 pm
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
- Oct 10th, 2023 8:05 pm
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
- Sep 19th, 2023 12:00 pm
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:00 pm
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 10th, 2023 8:13 pm
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
- Jul 19th, 2023 12:00 pm
Tempest to Present at the Jefferies Global Healthcare Conference
- May 31st, 2023 8:05 pm
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
- May 25th, 2023 9:00 pm
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 19th, 2023 8:05 pm
Scroll